Una Lee
Overview
Explore the profile of Una Lee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
362
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Torosis M, Carey E, Christensen K, Kaufman M, Kenton K, Kotarinos R, et al.
Obstet Gynecol
. 2024 Feb;
143(4):595-602.
PMID: 38387036
Objective: To develop evidence- and consensus-based clinical practice guidelines for management of high-tone pelvic floor dysfunction (HTPFD). High-tone pelvic floor dysfunction is a neuromuscular disorder of the pelvic floor characterized...
2.
Shapiro K, Anger J, Cameron A, Chung D, Daignault-Newton S, Ippolito G, et al.
Neurourol Urodyn
. 2023 Nov;
43(2):407-414.
PMID: 38032120
Introduction: Onabotulinumtoxin A (BTX-A) is a well-established treatment for overactive bladder (OAB). The American Urological Association (AUA) 2008 Antibiotic Best Practice Statement (BPS) recommended trimethoprim-sulfamethoxazole or fluoroquinolone for cystoscopy with...
3.
Wang C, Badalato G, Hartsell L, Lee U, Polland A
Urology
. 2023 Jul;
179:206-210.
PMID: 37406863
N/A.
4.
Du C, Lee W, Lucioni A, Kobashi K, Lee U
Urol Pract
. 2023 Jun;
7(4):288-293.
PMID: 37317441
Introduction: Patient education materials are widely used vehicles to provide patients with health education. While the Joint Commission recommends patient education materials not exceed the 5th grade level and the...
5.
6.
Lane G, Gracely A, Uberoi P, Lee U, Smith A, Anger J, et al.
Neurourol Urodyn
. 2021 Mar;
40(4):986-993.
PMID: 33719145
Introduction: There is a paucity of patient reported outcome measure (PROM) data for women with urethral strictures. To address this gap, we aim to evaluate change in PROM among women...
7.
Pezzella A, McCrery R, Lane F, Benson K, Taylor C, Padron O, et al.
Neurourol Urodyn
. 2021 Jan;
40(2):714-721.
PMID: 33508155
Aims: Sacral neuromodulation (SNM) is a guideline-recommended treatment with proven therapeutic benefit for urinary urgency incontinence (UUI) patients. The Axonics® System is the first Food and Drug Administration-approved rechargeable SNM...
8.
Benson K, McCrery R, Taylor C, Padron O, Blok B, De Wachter S, et al.
Neurourol Urodyn
. 2020 Apr;
39(5):1482-1488.
PMID: 32339339
Aims: Sacral neuromodulation (SNM) is a guideline-recommended treatment for voiding dysfunction including urgency, urge incontinence, and nonobstructive retention as well as fecal incontinence. The Axonics® System is a miniaturized, rechargeable...
9.
McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, et al.
J Urol
. 2019 Oct;
203(1):192.
PMID: 31580190
No abstract available.
10.
McCrery R, Lane F, Benson K, Taylor C, Padron O, Blok B, et al.
J Urol
. 2019 Jul;
203(1):185-192.
PMID: 31347955
Purpose: Sacral neuromodulation is a guideline recommended treatment of urinary dysfunction and fecal incontinence in patients in whom conservative treatments have failed. Historically sacral neuromodulation has been delivered using a...